MGMT 状态作为胶质母细胞瘤的临床生物标志物。
MGMT Status as a Clinical Biomarker in Glioblastoma.
机构信息
Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
出版信息
Trends Cancer. 2020 May;6(5):380-391. doi: 10.1016/j.trecan.2020.02.010. Epub 2020 Mar 27.
Abstract
Glioblastoma is the most common primary malignant brain tumor. Although current standard therapy extends median survival to ~15 months, most patients do not have a sustained response to treatment. While O-methylguanine (O-MeG)-DNA methyltransferase (MGMT) promoter methylation status is accepted as a prognostic and promising predictive biomarker in glioblastoma, its value in informing treatment decisions for glioblastoma patients remains debatable. Discrepancies between MGMT promoter methylation status and treatment response in some patients may stem from inconsistencies between MGMT methylation and expression levels in glioblastoma. Here, we discuss MGMT as a biomarker and elucidate the discordance between MGMT methylation, expression, and patient outcome, which currently challenges the implementation of this biomarker in clinical practice.
摘要
胶质母细胞瘤是最常见的原发性恶性脑肿瘤。尽管目前的标准治疗将中位生存期延长至约 15 个月，但大多数患者对治疗没有持续的反应。虽然 O-甲基鸟嘌呤（O-MeG）-DNA 甲基转移酶（MGMT）启动子甲基化状态被认为是胶质母细胞瘤的一种预后和有前途的预测生物标志物，但它在告知胶质母细胞瘤患者治疗决策方面的价值仍存在争议。在一些患者中，MGMT 启动子甲基化状态与治疗反应之间的差异可能源于胶质母细胞瘤中 MGMT 甲基化和表达水平之间的不一致性。在这里，我们讨论了 MGMT 作为生物标志物，并阐明了 MGMT 甲基化、表达和患者预后之间的差异，这目前对该生物标志物在临床实践中的应用提出了挑战。
相似文献
1
MGMT Status as a Clinical Biomarker in Glioblastoma.MGMT 状态作为胶质母细胞瘤的临床生物标志物。
Trends Cancer. 2020 May;6(5):380-391. doi: 10.1016/j.trecan.2020.02.010. Epub 2020 Mar 27.
2
Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.有安全边际的启动子甲基化临界值选择胶质母细胞瘤患者入组避免替莫唑胺治疗的临床试验：四项临床试验的汇总分析。
Clin Cancer Res. 2019 Mar 15;25(6):1809-1816. doi: 10.1158/1078-0432.CCR-18-3181. Epub 2018 Dec 4.
3
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.MGMT 启动子甲基化是预测剂量强化替莫唑胺再挑战获益的强预后生物标志物：DIRECTOR 试验。
Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5.
4
The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.胶质母细胞瘤中 MGMT 启动子甲基化的预后价值：临床试验的荟萃分析。
J Cell Physiol. 2018 Jan;233(1):378-386. doi: 10.1002/jcp.25896. Epub 2017 May 16.
5
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.MGMT 启动子甲基化状态和 MGMT 及 CD133 免疫组化表达作为替莫唑胺联合放疗治疗胶质母细胞瘤患者的预后标志物。
J Transl Med. 2012 Dec 17;10:250. doi: 10.1186/1479-5876-10-250.
6
Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.在接受替莫唑胺治疗的原发性胶质母细胞瘤患者中，MMR、MGMT 启动子甲基化和蛋白表达对总生存期和无进展生存期的影响。
Int J Mol Sci. 2023 Mar 24;24(7):6184. doi: 10.3390/ijms24076184.
7
The Impact of Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma.启动子甲基化和替莫唑胺治疗对塞尔维亚原发性胶质母细胞瘤患者的影响
Medicina (Kaunas). 2019 Feb 1;55(2):34. doi: 10.3390/medicina55020034.
8
Predictive value of MGMT promoter methylation on the survival of TMZ treated -mutant glioblastoma.MGMT 启动子甲基化对替莫唑胺治疗的突变型胶质母细胞瘤患者生存的预测价值。
Cancer Biol Med. 2021 Feb 15;18(1):272-282. doi: 10.20892/j.issn.2095-3941.2020.0179.
9
Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.采用定量 MethyQESD 方法研究原发性胶质母细胞瘤中 MGMT 启动子甲基化的定量水平与总生存期的相关性。
J Clin Pathol. 2020 Feb;73(2):112-115. doi: 10.1136/jclinpath-2019-206104. Epub 2019 Aug 17.
10
MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?胶质母细胞瘤患者 MGMT 启动子甲基化：甲基化敏感高分辨率熔解曲线分析优于甲基化敏感聚合酶链反应检测吗？
J Neurosurg. 2019 Mar 1;130(3):780-788. doi: 10.3171/2017.11.JNS171710. Epub 2018 May 4.
引用本文的文献
1
Unraveling epigenetic drivers of immune evasion in gliomas: mechanisms and therapeutic implications.揭示胶质瘤免疫逃逸的表观遗传驱动因素：机制与治疗意义
Front Immunol. 2025 Aug 25;16:1633338. doi: 10.3389/fimmu.2025.1633338. eCollection 2025.
2
Circadian variation in MGMT promoter methylation and expression predicts sensitivity to Temozolomide in glioblastoma.MGMT启动子甲基化和表达的昼夜节律变化可预测胶质母细胞瘤对替莫唑胺的敏感性。
Res Sq. 2025 Aug 29:rs.3.rs-7411649. doi: 10.21203/rs.3.rs-7411649/v1.
3
Glioblastoma: A Multidisciplinary Approach to Its Pathophysiology, Treatment, and Innovative Therapeutic Strategies.胶质母细胞瘤：关于其病理生理学、治疗及创新治疗策略的多学科方法
Biomedicines. 2025 Aug 2;13(8):1882. doi: 10.3390/biomedicines13081882.
4
Immune intrinsic escape signature stratifies prognosis, characterizes the tumor immune microenvironment, and identifies tumorigenic PPP1R8 in glioblastoma multiforme patients.免疫内在逃逸特征可对多形性胶质母细胞瘤患者的预后进行分层，描绘肿瘤免疫微环境，并鉴定致瘤性PPP1R8。
Front Immunol. 2025 Aug 6;16:1577920. doi: 10.3389/fimmu.2025.1577920. eCollection 2025.
5
Going viral: targeting glioblastoma using oncolytic viruses.病毒传播：使用溶瘤病毒靶向胶质母细胞瘤
Immunother Adv. 2025 Jul 25;5(1):ltaf024. doi: 10.1093/immadv/ltaf024. eCollection 2025.
6
Multicellular Model of Temozolomide Resistance in Glioblastoma Reveals Phenotypic Shifts in Drug Response and Migratory Potential.胶质母细胞瘤中替莫唑胺耐药的多细胞模型揭示了药物反应和迁移潜能的表型转变。
bioRxiv. 2025 Jul 11:2025.07.08.663674. doi: 10.1101/2025.07.08.663674.
7
Siramesine induced cell death of glioblastoma through inactivating the STAT3-MGMT signaling pathway.西拉莫辛通过使STAT3-MGMT信号通路失活诱导胶质母细胞瘤细胞死亡。
J Transl Med. 2025 Jul 10;23(1):780. doi: 10.1186/s12967-025-06693-y.
8
Glioma promotes macrophage immunosuppressive phenotype through ANXA1 in a methionine metabolism-dependent manner.胶质瘤通过膜联蛋白A1以甲硫氨酸代谢依赖的方式促进巨噬细胞免疫抑制表型。
Discov Oncol. 2025 Jul 6;16(1):1269. doi: 10.1007/s12672-025-03112-y.
9
Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.克服胶质瘤中的替莫唑胺耐药性：最新进展与机制洞察
Acta Neuropathol Commun. 2025 Jun 5;13(1):126. doi: 10.1186/s40478-025-02046-4.
10
Beyond the Promoter: Total MGMT Gene Methylation Modulates Response to DNA Alkylating Agents in Glioma.启动子之外：MGMT基因整体甲基化调控胶质瘤对DNA烷化剂的反应
Mol Cancer Ther. 2025 Jun 4. doi: 10.1158/1535-7163.MCT-24-0977.
本文引用的文献
1
Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients.预测 IDH 野生型胶质母细胞瘤患者同质队列中的 MGMT 状态。
Acta Neuropathol Commun. 2019 Jun 5;7(1):89. doi: 10.1186/s40478-019-0745-z.
2
CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.用于癌细胞系综合跨数据库基因组学和药物基因组学分析的CellMinerCDB
iScience. 2018 Dec 21;10:247-264. doi: 10.1016/j.isci.2018.11.029. Epub 2018 Dec 12.
3
Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma.错配修复缺陷型复发性胶质母细胞瘤的遗传、表观遗传和免疫特征分析。
Clin Cancer Res. 2019 Mar 15;25(6):1828-1837. doi: 10.1158/1078-0432.CCR-18-1892. Epub 2018 Dec 4.
4
Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.有安全边际的启动子甲基化临界值选择胶质母细胞瘤患者入组避免替莫唑胺治疗的临床试验：四项临床试验的汇总分析。
Clin Cancer Res. 2019 Mar 15;25(6):1809-1816. doi: 10.1158/1078-0432.CCR-18-3181. Epub 2018 Dec 4.
5
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.CBTRUS统计报告：2011 - 2015年美国原发性脑肿瘤及其他中枢神经系统肿瘤诊断情况
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86. doi: 10.1093/neuonc/noy131.
6
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.MGMT 启动子甲基化状态检测指导胶质母细胞瘤的治疗：基于新出现的证据和当前的挑战来改进方法。
Neuro Oncol. 2019 Feb 14;21(2):167-178. doi: 10.1093/neuonc/noy132.
7
Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide).在接受烷基化化疗（替莫唑胺）的胶质瘤患者中，MGMT 甲基化和蛋白表达的一致性关联验证了其为有利的预后因素。
Sci Rep. 2018 Apr 30;8(1):6704. doi: 10.1038/s41598-018-25169-2.
8
Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.对350例胶质瘤和神经节胶质瘤系列中三种分析MGMT甲基化状态方法的比较评估。
Pathol Res Pract. 2017 Dec;213(12):1489-1493. doi: 10.1016/j.prp.2017.10.007. Epub 2017 Oct 10.
9
Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis.排除非肿瘤细胞分析后 O-6-甲基鸟嘌呤-DNA 甲基转移酶（MGMT）蛋白表达在胶质母细胞瘤中的预后价值。
Neuropathol Appl Neurobiol. 2018 Feb;44(2):172-184. doi: 10.1111/nan.12415. Epub 2017 Jun 28.
10
Role of Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications.胶质母细胞瘤患者诊断和复发时甲基化状态的作用：临床意义。
Oncologist. 2017 Apr;22(4):432-437. doi: 10.1634/theoncologist.2016-0254. Epub 2017 Mar 8.
Zotero 插件